Table 4.
Selected applications of peptide-drugconjugates.
| Peptide | Drug/Vaccine | Indications | Reference |
|---|---|---|---|
| Somatostatin peptide analogue | 177Lu-dotate | Gastroenteropancreatic neuroendocrine tumors | [168] |
| Di-amino acid | Melflufen | Multiple myeloma | [169] |
| Arginine-glycine-aspartic acid | Naproxen/Ibuprofen | Anti-inflammatory/additives therapy with anti-cancer drugs to provide specific targeted delivery | [170] |
| Asparagine-glycine-arginine | Naproxen/ Ibuprofen |
||
| Arginine-glycine-aspartic acid/Asparagine-glycine-arginine | Ketoprofen | Anti-cancer therapy | [171] |
| AE147 peptide | Docetaxel | Advanced therapy for metastatic tumor | [172] |
| Gonadotropin-releasing hormone I/II | Daunorubicin | Targeted tumor therapy with high binding affinity and provides apoptotic effects | [173] |
| Dimethylmaleic anhydride | Doxorubicin | Targeted tumor therapy | [174] |
| Lysine | Neomycin-B | Antibiotics mainly evaluate their activity against gram-positive bacteria | [175] |
| Disulfide | Kanamycin | Successfully shows the activity in Mycobacterium tuberculosis | [176] |
| Polylactide-co-glycolide | Pyridopyrimidine derivatives | Anti-tubercular activity | [177] |
| Dipeptide | Cinnamic acid | Anti-protozoal agent | [178] |
| Ubiquicidin | Coumarin derivatives | Anti-fungal agent | [179] |
| Self-adjuvanting peptide vaccine conjugated toll-like receptor 7 agonists | CoVac501 | SARS-CoV-2 and other infectious diseases | [162] |